Literature DB >> 16487446

Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease.

Giovanni Targher1, Lorenzo Bertolini, Stefano Rodella, Giacomo Zoppini, Luciano Zenari, Giancarlo Falezza.   

Abstract

OBJECTIVES: To assess associations between the activity of hypothalamo-pituitary-adrenal (HPA) axis and liver histology in patients with nonalcoholic fatty liver disease (NAFLD). DESIGN AND PATIENTS: In a cross-sectional study, we enrolled 50 consecutive, overweight, NAFLD patients and 40 control subjects who were comparable for age, sex and body mass index (BMI). MEASUREMENTS: NAFLD (by liver biopsy), HPA axis activity (by 24-hour urinary free cortisol [UFC] excretion and serum cortisol levels after 1 mg dexamethasone), insulin resistance (by homeostasis model assessment: HOMA-IR), and metabolic syndrome (MetS) features.
RESULTS: NAFLD patients had markedly higher (P < 0.001) 24-h UFC (149 +/- 24 vs. 90 +/- 16 nmol/day) and postdex suppression cortisol concentrations (32 +/- 10 vs. 16 +/- 7 nmol/l) than controls. The MetS and its individual components were more frequent among NAFLD patients. The marked differences in urinary/serum cortisol concentrations that were observed between the groups were little affected by adjustment for age, sex, BMI, waist circumference, systolic blood pressure, triglycerides, homeostasis model assessment for insulin resistance score and presence of diabetes. Importantly, 24-h UFC and postdex cortisol concentrations strongly correlated to hepatic necroinflammatory grade (P < 0.01) and fibrosis stage (P < 0.001) among NAFLD patients. By logistic regression analysis, 24-h UFC (odds ratio (OR) 1.80, 95%CI 1.3-2.8) or postdex cortisol concentrations (OR 1.95, 95%CI 1.4-3.1) independently predicted the severity of hepatic fibrosis, but not necroinflammation, after adjustment for potential confounders.
CONCLUSIONS: These results suggest that NAFLD patients have a subtle, chronic overactivity in the HPA axis (that is closely associated with the severity of liver histopathology) leading to subclinical hypercortisolism that might be implicated in the development of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487446     DOI: 10.1111/j.1365-2265.2006.02466.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  35 in total

1.  Estrogen suppresses heptatic IκB expression during short-term alcohol exposure.

Authors:  Eric G Lee; Bethany M Mickle-Kawar; Lester A Reinke; Randle M Gallucci
Journal:  Inflamm Res       Date:  2012-06-06       Impact factor: 4.575

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 3.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 4.  Obstructive sleep apnea syndrome and fatty liver: association or causal link?

Authors:  Mohamed-H Ahmed; Christopher-D Byrne
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

Review 5.  Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology.

Authors:  Davide Gnocchi; Carlo Custodero; Carlo Sabbà; Antonio Mazzocca
Journal:  J Mol Med (Berl)       Date:  2019-04-05       Impact factor: 4.599

Review 6.  Hypertension and hepatic steatosis.

Authors:  Matthew J Brookes; Tariq H Iqbal; Brian T Cooper
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

7.  Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis.

Authors:  Yuzhi Jia; Navin Viswakarma; Tao Fu; Songtao Yu; M Sambasiva Rao; Jayme Borensztajn; Janardan K Reddy
Journal:  Gene Expr       Date:  2009

Review 8.  Systemic illness.

Authors:  Marta Bondanelli; Maria Chiara Zatelli; Maria Rosaria Ambrosio; Ettore C degli Uberti
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

9.  Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients.

Authors:  Leyla Nazal; Arnoldo Riquelme; Nancy Solís; Margarita Pizarro; Alex Escalona; Mauricio Burotto; Juan Ignacio Méndez; Catalina Saint-Jean; María José Concha; Stefano Giovanni; Diego Awruch; Arturo Morales; Rene Baudrand; Gonzalo Carrasco; María Angélica Domínguez; Oslando Padilla; Manuel Espinoza; Juan Francisco Miquel; Flavio Nervi; Marco Arrese
Journal:  Obes Surg       Date:  2010-01-12       Impact factor: 4.129

10.  GR-mediated FTO transactivation induces lipid accumulation in hepatocytes via demethylation of m6A on lipogenic mRNAs.

Authors:  Yun Hu; Yue Feng; Luchu Zhang; Yimin Jia; Demin Cai; Shu-Bing Qian; Min Du; Ruqian Zhao
Journal:  RNA Biol       Date:  2020-03-09       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.